“Green light” in the use of therapy monoclonal antibodies its long action GlaxoSmithKline against coronavirus lit today, Thursday (2/12) its drug service Of Britain, the MHRA, at the time the British company announced that this treatment remains effective against it Omicron mutation.
In particular, the sotrovimab, which is also known by its brand name Xevudy, proved to be safe and effective for reducing the risk of hospitalization and death in people with mild to moderate infection from COVID-19 who were at increased risk of developing a severe form of the disease, the MHRA said in a statement.
This treatment of long-acting monoclonal antibodies allows, thanks to a single dose, to reduce the risk of hospitalization and death by 79% in adults at high risk of developing symptoms, the British regulator noted. The British Drug Administration has recommended the use of Xevudy as soon as possible within five days of the onset of symptoms.
Sotrovimab: When is the data expected to be updated?
GSK assured that this treatment, which it developed together with the biotechnology laboratory in California, Vir Biotechnology, USA, remains active against the basic mutations of the new Omicron variant of the new coronavirus. “To date, sotrovimab has shown that it continues to work against all, as identified by the World Health Organization (WHO), variants of concern and interest” of the new coronavirus, according to the company.
In a statement, GlaxoSmithKline also said that laboratory tests and research on hamsters had shown that the sotrovimab antibody cocktail acted against viruses that had been biotechnologically engineered to carry a number of characteristic mutations of the Omicron variant, according to the APE-MP.
Tests are ongoing to confirm results against all Omicron mutations and one The data is expected to be updated by the end of the year, the British company concludes in its announcement.
The drug was approved by the European Commission at the end of June one of the five most promising treatments for COVID-19. It is also the second treatment for the disease caused by the new coronavirus approved in one month in Britain, after molnupiravir, the pill against COVID-19 of the American laboratory Merck, which was approved in early November.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
